Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-18
2009-02-24
Saeed, Kamal A (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S373000, C514S037000, C514S375000, C514S379000, C548S165000, C548S209000, C548S221000, C548S241000
Reexamination Certificate
active
07495020
ABSTRACT:
A class of 2-aryloxy-2-arylalkanoic acids comprises compounds that are potent agonists of PPAR alpha and/or gamma, and are therefore useful in the treatment, control or prevention of non-insulin dependent diabetes mellitus (NIDDM), hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, obesity, vascular restenosis, inflammation, and other PPAR alpha and/or gamma mediated diseases, disorders and conditions.
REFERENCES:
patent: 3378582 (1968-04-01), Bolhofer
patent: 3517050 (1970-06-01), Bolhofer
patent: 3787423 (1974-01-01), Bolhofer
patent: 3816446 (1974-06-01), Bolhofer
patent: 3953465 (1976-04-01), Bolhofer
patent: 4125729 (1978-11-01), Trust et al.
patent: 4125732 (1978-11-01), McEvoy et al.
patent: 4168385 (1979-09-01), Trust et al.
patent: 4748272 (1988-05-01), Youssefyeh
patent: 4820715 (1989-04-01), Monkovic et al.
patent: 5059610 (1991-10-01), Huang et al.
patent: 5177095 (1993-01-01), Greenlee et al.
patent: 5183810 (1993-02-01), Greenlee et al.
patent: 5240938 (1993-08-01), Greenlee et al.
patent: 5264439 (1993-11-01), Greenlee et al.
patent: 5334598 (1994-08-01), Bagley et al.
patent: 5374638 (1994-12-01), Dhanoa et al.
patent: 5391566 (1995-02-01), Chakravarty et al.
patent: 5401745 (1995-03-01), Bagley et al.
patent: 5420133 (1995-05-01), Dhanoa et al.
patent: 5449682 (1995-09-01), Greenlee et al.
patent: 5519138 (1996-05-01), Ries et al.
patent: 5538991 (1996-07-01), Ashton et al.
patent: 5559135 (1996-09-01), Ashton et al.
patent: 5565485 (1996-10-01), Bagley et al.
patent: 5596124 (1997-01-01), Cary et al.
patent: 5668176 (1997-09-01), Bagley et al.
patent: 5688974 (1997-11-01), Devine et al.
patent: 5708186 (1998-01-01), Devine et al.
patent: 5767310 (1998-06-01), Bagley et al.
patent: 5821256 (1998-10-01), Dorsch et al.
patent: 5994356 (1999-11-01), Pieper et al.
patent: 6110963 (2000-08-01), Malamas
patent: 0 617 001 (1996-04-01), None
patent: WO 95/03044 (1995-02-01), None
patent: WO 96/09818 (1996-04-01), None
patent: WO 97/21693 (1997-06-01), None
patent: WO 97/21700 (1997-06-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/28137 (1997-08-01), None
patent: WO 98/55454 (1998-12-01), None
patent: WO 99/58519 (1999-11-01), None
patent: WO 99/58521 (1999-11-01), None
patent: WO 00/74666 (2000-12-01), None
patent: WO 01/60807 (2001-08-01), None
patent: WO 02/44113 (2002-06-01), None
HCAPLUS 1979:566381.
CAPLUS 1987:439422.
HCAPLUS 1989:75063.
HCAPLUS 1999:572043.
Thomas F. Walsh, et al, “Potent Dual Antagonists of Endothelin and Angiotensin II Receptors Derived from alpha-Phenoxyphenylacetic Acids (Part III)”, 1995, pp. 1155-1158, vol. 5, No. 11, Bioorganic & Medicinal Chemistry Letters.
T.C. Asthana, et al, “Alpha-Phenoxy- & Thiophenoxyphenylacetic Acid Derivatives as Hypoglycaemic Agents”, 1970, pp. 1086-1095, vol. 8, Indian Journal of Chemistry.
Shamina M. Rangwala, et al, “Stereoselective Effects of Chiral Clofibric Acid Analogs on Rat Peroxisome Proliferator-Activated Receptor alpha (rPPARalpha) Activation and Peroxisomal Fatty Acid Beta-Oxidation” Chirality 9:37-47 (1997).
Daljit S. Shanoa, et al, “(Dipropylphenoxy)phenylacetic Acids: A New Generation of Nonpeptide Angiotensin II Receptor Antagonists”, J. Med. Chem. 1993, 36, 3738-3742.
Holly T. Beauchamp, et al, “In Vivo Receptor Occupancy of the Angiotensin II Receptor by Nonpeptide Antagonists: Relationship to In Vitro Affinities and In Vivo Pharmacologic Potency”, JPET, vol. 272, No. 2, 612-618, 1995.
D. Pitre, et al, “Mezzi Di Contrasto Radiologici”, Il Farmaco—Ed. Sc.—vol. 27—No. 5, 1972, pp. 408-418.
G. Tilly, “Synthese de nouveaux moyens de constraste radiologiques pour la cholecystographie”, Chimie Therapeutique, 1967, pp. 57-65.
H. Cassebaum, et al “Neue intravenos applizierbare Gallenkontrastmittel”, pp. 470-474, 1967.
Giuseppe Campiani, et al, “Pyrrolobenzothiazepinones and Pyrrolobenzoxazepinones: Novel and Specific Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors with Antiviral Activity”, J. Med. Chem. 1996, 39, 2672-2680.
Adams Alan D.
Berger Joel P.
Dropinski James F.
Elbrecht Alexander
Jones A. Brian
Daniel Mark
McGinnis James L.
Merck & Co. , Inc.
Saeed Kamal A
LandOfFree
2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-aryloxy-2-arylalkanoic acids for diabetes and lipid disorders will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4097414